AXS-05 (dextromethorphan and bupropion) oral tablets
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Major Depressive Disorder
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Depression
Trial Timeline
Jul 8, 2019 → Oct 23, 2020
NCT ID
NCT04039022About AXS-05 (dextromethorphan and bupropion) oral tablets
AXS-05 (dextromethorphan and bupropion) oral tablets is a phase 3 stage product being developed by Axsome Therapeutics for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04039022. Target conditions include Major Depressive Disorder, Treatment Resistant Depression, Depression.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04039022 | Phase 3 | Completed |
Competing Products
20 competing products in Major Depressive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 23 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 33 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 85 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 52 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 33 |
| LY2216684 + Placebo + Lorazepam | Eli Lilly | Phase 1 | 33 |
| LY2216684 + SSRI | Eli Lilly | Phase 3 | 77 |